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A novel microfluidic 3D platform 
for culturing pancreatic ductal 
adenocarcinoma cells: comparison 
with in vitro cultures and in vivo 
xenografts
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Manoli2, Julia Schuette1, Christian Schmees1, Armando Casazza3, Martin Stelzle1 & Annarosa 
Arcangeli  2
The integration of microfluidics and cell biology has reached a significant milestone with the 
development of “organ-on-chips”, smart technological platforms that, once applied to the study 
of human diseases, such as cancer, might ultimately contribute to design personalised treatments 
and hence improve health outcomes. This paper reports that the combination of microfluidics and 
dielectrophoresis (DEP) allows to culture different pancreatic ductal adenocarcinoma (PDAC) human 
cell lines into a cyclic olefin polymer (COP) chamber (HepaChip®), enriched by the extracellular 
matrix (ECM) protein collagen. We show that PDAC cells cultured into the HepaChip® (1) are vital 
and grow, provided they properly attach to collagen; (2) show morphological appearance and growth 
characteristics closer to those of cells grown as spheroids than as classical 2 dimensional (2D) in vitro 
cultures. Finally, preliminary experiments show that PDAC cells respond to high doses of Cisplatin 
perfused through the chip. Overall, the present microfluidic platform could be exploited in the future for 
a personalised approach to PDAC.
The deciphering of tumour biomolecular features and growth dynamics and the identification of novel targeted 
therapeutic strategies is being one of the major challenges in oncological research. Different platforms, based on 
either in vitro cell cultures in two dimension (2D) or in vivo animal models, have been proposed and employed 
for pre-clinical testings1, 2. While in vitro 2D cultures have been the cornerstone of pre-clinical cancer research, 
there is increasing evidence that cells grown in 2D monolayers do not accurately reflect the biological complex-
ity of tumours. In particular, they lack the complex extracellular matrix (ECM)-cancer interactions as well as 
intra-tumoral gradients in pH, oxygen and nutrients, which have been found in cancers in vivo. These weaknesses 
can explain why many drugs, that pass pre-clinical in vitro testing, fail in the patients3–6. On the other hand, 
“classical” in vivo pre-clinical mouse models, e.g. subcutaneous or orthotopic xenografts of human tumour cells 
in immuno-compromised mice, poorly recapitulate the proper tumour behaviour and undermine the impact of 
the tumour microenvironment, in particular of acquired immunity. Moreover, animal models are expensive, time 
consuming and under some aspects “non-ethical”4, 5.
Scientists hence realised the necessity of using more complex three dimensional (3D) cell cultures for bet-
ter understanding tumour characteristics in a proper microenvironment and testing the responses to different 
drugs. Generally, 3D cultures can more closely mimic physiological conditions over 2D monolayers, as they more 
accurately reflect the architecture and bio-mechanical properties of the tumour tissue. In addition, 3D cultures 
can reproduce several parameters of tumour microenvironment, including oxygen and nutrient gradients as well 
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as the development of a dormant tumour region7, 8. Overall, 3D cultures allow to monitor cell growth dynamics 
and response to treatments more appropriately, and could hence fill the gap between in vitro and in vivo systems 
for preclinical oncological research. As a result, there has been increasing focus in developing 3D techniques, 
and many different platforms have been proposed, with different grades of complexity and expression of tumour 
microenvironmental conditions5, 9.
A further improvement in this field could derive from the integration of microfluidics and cell biology, which 
has recently reached a significant milestone with the development of “organ-on-chip” technologies. What began 
at the turn of the millennium as simple demonstrations of biological cells being transported and manipulated in 
microchannels for basic short-term analysis, has now advanced to the point where we can engineer living cellular 
microsystems with controllable microenvironments that behave and function – with organ-level complexity – like 
their counterparts in vivo10–14. Organ-like features include continuous perfusion and physiological cell–matrix 
and cell–cell interactions. More recently, the “organ on chip” technology has been transferred to study human 
disease models, including cancer15–20. As a further step, the combination of microfluidics and dielectrophoresis 
(DEP) to assemble primary human cells, has enabled the automated in vitro construction of micro-organs, which 
mimic proper in vivo structures. As a unique feature of organ-on-chip technology, the use of DEP selectively 
assembles only viable cells21, 22. For the HepaChip® organ-specific 3D cell culture chambers are designed and 
validated by multiphysics simulations and realised by injection moulding of cyclic olefin polymer (COP)21, 23, 24. 
Proprietary surface functionalization enables selective deposition of ECM proteins in a simple perfusion pro-
cess25. High resolution optical imaging of micro-organs along with the complete set of staining technologies is 
possible due to the exceptional optical properties of COP.
We applied these concepts to create a novel platform for studying pancreatic ductal adenocarcinoma (PDAC), 
one of the human cancers with worst prognosis, for which the design of novel therapeutic options is urgently 
needed. For these reasons, various model systems are being developed, from in vitro 2D and 3D cell cultures, to 
whole animal models26.
We here provide evidence that human PDAC cells can be cultured onto a novel microfluidic chamber, the 
HepaChip®, maintaining cell vitality and displaying appropriate morphological appearance, growth characteris-
tics and response to chemotherapeutic drugs.
Materials and Methods
Cell lines. The PDAC cell lines; PANC1, BxPC3 and MiaPaCa2 were used for the experiment. The Panc1 and 
MiaPaCa2 cells harbour mutation in KRAS and TP53, homozygous deletion (HD) in CDKN2A/p16 and wild 
type (WT) SMAD4, while BxPC3 cells harbour mutation in TP53, HD in SMAD4 and WT KRAS27.
Two dimensional cell culture (2D). PANC1 and MiaPaCa2 cells were cultured using Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) (Hyclone, SH30070.03) and 4 mM 
glutamine. BxPC3 was cultured using RPM1-1640 medium (EuroClone) supplemented with 10% FBS (Hyclone, 
SH30070.03) and 2 mM glutamine (Sigma). Cells were cultured in a humidified 5% CO2 at 37 °C.
Growth Curve and Live/Dead cell imaging. Ten thousand cells were seeded in each well of a 96 well plate in 
200 µL of media. Cell density was estimated every 24 h by manual counting in the presence of trypan blue dye to 
exclude dead cells. After 48 h of culturing cells were stained with Calcein AM (2 µg/mL) (Molecular Probes) and 
Propidium Iodide (PI) (10 µg/mL) (Sigma) for 20 minutes. Then washed with Phosphate-Buffered Saline (PBS) 
and Images were taken using Nikon Eclipse TE300 florescence microscope.
Phalloidin staining. Thin glass cover slips were ethanol and flame sterilised. The cells were seeded on the glass 
cover slips for 24 h. The unattached cells were washed away with PBS and cells were fixed with 4% methanol-free 
formaldehyde (Thermo scientific) for 20 minutes at room temperature. Cells were permeabilised with 0.01% 
Triton-X for 5 minutes at room temperature, washed with PBS. Nonspecific sites were blocked using 10% BSA for 
1 h. Then cells were stained using rhodamine conjugated Phalloidin (Sigma), followed by nucleus staining using 
4′,6-diamidino-2-phenylindole (DAPI; Invitrogen). Images were captured using confocal microscope (Nikon 
Eclipse TE2000-U).
Drug Treatment and analysis of drug efficacy. Ten thousand PANC1 cells were seeded per well (96 well plate). 
After 24 h of culturing, cells were treated with Cisplatin (Sigma) of 0, 1, 2.5,5,10,25,50 and 100 µM concentration. 
After 24 h of drug treatment, cells were detached using trypsin and counted manually using trypan blue as above.
Three dimensional cell culture (3D). Three dimensional spheroids were generated using liquid over-
lay technique (U tube technique). Cells were treated with trypsin and counted using trypan blue. Subsequently 
cells were seeded onto agarose-coated (50 µL, 1.5% agarose/well) 96 well plate in 100 µL of medium28. After 72 h, 
100 µL medium was added and afterwards, every 48 h, 50% of the supernatant was replaced with fresh medium. 
Spheroids were cultured at 37 °C in a humidified atmosphere containing 5% CO2 in air.
Growth Curve and Live/Dead cell imaging. Five hundred cells were seeded on agarose coated 96 well plate. 
Spheroids were imaged using bright field microscopy (Nikon) every day with a 10x objective. Image resolution 
was 0.757 µm/pix. Spheroid volume was calculated using SpheroidSizer program as reported by Chen W. et al.28. 
After 72 h of cell seeding, cells were stained by adding fresh medium containing Calcein AM (2 µg/mL) and PI 
(10 µg/ mL), incubated for 20 minutes and then washed with PBS. Images were taken using Nikon Elipse TE300 
florescence microscope.
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Phalloidin staining. After 72 h of culturing, spheroids were fixed with 4% formaldehyde, then permeabilised 
using 0.01% Triton-X for 5 minutes, and washed with PBS. Cells were then blocked using 10% BSA for 1 h, and 
then stained using rhodamine conjugated Phalloidin. Nucleus was stained using DAPI. Images were captured 
using confocal microscope (Nikon Eclipse TE2000-U).
Drug Treatment and analysis of drug efficacy. For drug treatment, 1000 PANC1 cells were seeded per well (96well 
plate). After 72 h, spheroids were treated with Cisplatin of 0, 5,10,20,50 and 100 µM concentration. Untreated 
spheroids were also cultured in parallel. Spheroids were maintained without changing medium for the whole 
experiment. After 72 h of drug treatment, 20 to 30 spheroids were collected, washed with PBS, dissociated using 
5 mM Ethylenediaminetetraacetic acid (EDTA) and incubated with PI (0.05 µg/mL) for 5 min. Stained cells were 
analysed using flow cytometer.
Microfluidic cell culture device (HepaChip®). The device technology was previously described21, 23, 24. 
Briefly, the device comprises eight identical cell chambers, containing three cell culture regions each, sized 
1 mm × 60 µm, i.e. 24 cell culture regions per chip. These culture regions were selectively coated with collagen to 
facilitate cell adhesion as reported before25. In brief, the regions were irradiated through a shadow mask by UV 
light to induce acid groups on the surface. Collagen was incubated from a 20 µM solution for 90 min and bound 
to these acid groups. After rinsing the chip was sealed with an adhesive foil (polyolefin cover foil, HJ-Bioanalytik 
Moenchengladbach). Chips (without cover foil) were manufactured by microfluidic ChipShop, Jena, by micro 
injection moulding.
On the side walls of each cell chamber electrodes are integrated which are used to generate an inhomogeneous 
high frequency electrical field. This gives rise to dielectrophoretic forces by which cells entering the cell chamber 
are drawn into the assembly areas. Only viable cells will be selectively assembled as only they exhibit intact cell 
membranes with their intracellular permittivity differing from that of the extracellular medium they are sus-
pended in.
The microfluidic devices were mounted in a fixture providing for fluidic, electrical, and thermal contact and 
control of the chip by an external periphery unit containing Polytetrafluoroethylene (PTFE) tubes and syringe 
pumps as well as function generator, amplifier and electronic heat control.
Cell assembly and culture in HepaChip®. Cells were suspended in a DEP medium exhibiting an especially low 
conductance of 80 to 200 µS/cm. It comprised 95 g/L sucrose, 1 g/L glucose, 57.9 mg/L sodium pyruvate, 28.4 mg/L 
calcium chloride and 24.6 mg/L MgSO4 (aq). From this suspension cells were assembled by DEP at a flow rate of 
100 µl/min, a peak to peak voltage between 140 and 150 V and a frequency of 350 kHz, for durations of 3 to 5 min.
After cell assembly, culture medium was perfused through the chip for 3 to 9 days at a perfusion rate of 
3.125 µl/min. During culture the chips were maintained at temperatures between 35 °C and 37 °C while the 
medium reservoirs were heated to between 37 °C and 39 °C. To make sure that no gas or air bubbles enter the 
microfluidic chips, a bubble trap was inserted in the inlet tubing of each chip. In this trap the medium flows 
underneath a gas permeable PTFE membrane where bubbles can exit but the medium is kept inside the system.
Viability assay in HepaChip®. Each day the cells in the microfluidic chip were stained with green fluorescent 
Calcein AM (2 µg/mL) and red fluorescent PI (10 µg/mL) in order to visualise viable cells in green and nuclei of 
dead or dying cells in red. After incubating with the staining solution for 20 min at 7 µL/min the chip was washed 
with culture medium before the perfused culture restarted. Images were captured with Nikon DS 2MBWc micro-
scope camera using Nikon Eclipse Ti.
Phalloidin staining in HepaChip®. The chip was flushed with 4% paraformaldehyde for 20 min at 15 µL/min 
to fix the cells. Next the cells were permeabilised by pumping phosphate buffered saline (PBS) with 1% triton X 
through the chip for 10 min at a flow rate of 50 µL/min. Then cells were stained with green fluorescent Phalloidin 
and DAPI in PBS for 20 min at 15 µL/min and finally washed with PBS at 50 µL/min. The cells in the chips were 
then imaged as those stained in the viability assay.
In vivo experiments on nu/nu mice. In vivo experiments were performed at Dival Toscana Srl, inside 
the Animal Facility of the University of Florence. All experiments on live vertebrates were performed in accord-
ance with relevant guidelines and regulations. We confirm that the Ethical Committee of the University of 
Firenze approved all the experiments described in this paper. Female, 9 weeks aged, athymic nude nu/nu mice 
(Envigo-Harlan Italy; Udine) were subcutaneously (s.c.) injected with 3 × 106 PANC1 cells per mouse. Mice were 
treated daily intraperitoneum (i.p.) with Cisplatin (10 mg/kg) (n = 4 masses) or with saline (n = 4 masses) for one 
week, starting the day the masses reached the measure of (0,2 × 0,2 cm). Tumour growth was monitored daily 
by measuring two perpendicular diameters; the volume of the tumour masses was calculated using the ellipsoid 
equation. At the end of the treatment, all mice were sacrificed, and tumour masses were collected measured and 
weighted.
Statistical analysis. Data are generally given as mean values ± standard error of the mean (SEM), with n 
indicating the number of independent experiments. When the mean ± standard deviation (SD) was calculated, 
it is indicated in the figure legend. Statistical comparisons between two groups of data were performed with the 
Mann-Whitney test.
Results
The aim of the present study was to demonstrate the feasibility of obtaining healthy and reproducible cultures 
of PDAC cells in a microfluidic chamber, which enables active assembly of cell aggregates and cultivation under 
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continuous and controlled perfusion. For this purpose, we used three different human PDAC cell lines (BxPC3, 
PANC1 and MiaPaCa2), whose growth characteristics were first analysed in 2D (Fig. 1) and spheroid 3D (Fig. 2) 
cultures. In 2D culture conditions, all the PDAC cells proliferate roughly at the same extent and with similar 
kinetics, reaching a plateau at about 3 × 105 cells/ml after 72 hours of incubation (Fig. 1A). As evident from 
phase contrast pictures in Fig. 1B, BxPC3 cells show a flattened morphology, with the tendency to grow as small 
“islands”. MiaPaCa2 cell cultures show two types of cells (1) Adherent cells with a mesenchymal morphology, with 
round body and more or less long and substrate adherent cytoplasmic extensions and (2) Round, less adherent 
cells. PANC1 display an intermediate morphology, not fully epithelial, more mesenchymal, but more adherent 
to the substrate compared to MiaPaCa2 cells. Roughly all the PDAC cells in 2D cultures are vital after 48 hours 
of incubation, as witnessed by the Calcein/PI staining (Fig. 1C). One of the functional characteristics of cancer is 
their propensity to migrate, an essential step for further metastatisation. Hence cancer cells are characterised by 
a peculiar organisation of their actin cytoskeleton which can underlie the formation of lamellipodia29. We then 
chose to determine the state of the actin cytoskeleton, determined by the Phalloidin staining, in the different 
PDAC cell lines as a functional indication of their pro-migratory propensity, and hence “cancerous” behaviour. 
Figure 1D shows that all PDAC cells have a cancer-type organisation of their cytoskeleton, with dendritic arrays 
of actin filaments.
When the cells were cultured as 3D, employing the U tube technique, PANC1 and MiaPaCa2 cells grew to 
form big spheroids, with a comparable growth rate over the 10 days’ culture period. On the other hand, BxPC3 
showed very low or null growth rate (Fig. 2A). As better evident from Fig. 2B, the three different PDAC cells 
formed spheroids with varying degree of compactness: both PANC1 and MiaPaCa2 cells gave rise to big and 
loosely compact spheroids. PANC1 spheroids were also characterised by branches of cells coming out from 
the originary spheroid mass. Moreover, they showed a clear distinction between tightly formed round central 
dormant and loosely ruffled peripheral cells. On the contrary, BxPC3 formed very small and highly compact 
spheroids, with only few scattered cells outgrowing from the originary mass, with no distinction between central 
and peripheral region. Calcein/PI staining (Fig. 2C) showed that the majority of cells in the spheroid were viable 
after 72 h of incubation. Furthermore, the PDAC cells in the spheroids showed an actin cytoskeleton compactly 
arranged, with short actin filament distributed around the periphery of cells, especially where cell-cell interaction 
and aggregation took place (Fig. 2D).
Figure 1. In vitro cell growth characteristics of PDAC cells in 2D culture conditions. (A) Comparison of growth 
rate among the PDAC cell lines in terms of increase in number of cells per day (n = 3). Data are means ± SEM 
of three separate experiments each carried out in triplicate. At the 0.05 level, the PANC1, MiaPaCa2 and BxPC3 
are not significantly different. (B) Microscopic images after 48 h of culturing of PDAC cell lines. Morphology 
was different among the cell lines. (C) Live and dead cells were stained by Calcein (Green) and PI (Red) 
respectively after 24 h of culturing. (D) Actin filaments were stained by rhodamine conjugated Phalloidin (Red) 
and nucleus was stained by DAPI (Blue). Scale bars in B and C represent 100 µm, in D represents 10 µm.
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The same PDAC cell lines were then cultured in a novel type of microfluidic cell culture chamber, the 
HepaChip®. Figure 3A shows the HepaChip®, with fluid inlet and outlet, microchannels addressing eight cell 
chambers and electrodes contacting the lateral faces of each cell chamber (Fig. 3B). When energised with a high 
frequency (typically 100 kHz to 1 MHz) voltage, an inhomogeneous electric field is generated as local field strength 
is modulated by the assembly ridges positioned between opposite faces of the cell chambers. Under the media 
conditions chosen (low conductivity medium) cells are attracted from the cell suspension onto the assembly 
ridges. Figure 3C shows a multiphysics simulation of hydrodynamic and electrical forces acting on cells. Each line 
represents the calculated trajectory of a cell, part of which are ending on assembly ridges. Simulations as shown 
here enable assessment and optimisation of assembly efficiency for a given 3D microstructure of the chamber, 
Figure 2. In vitro cell growth characteristics of PDAC cells in 3D culture conditions. (A) Comparison of 
growth rate between the PDAC cell lines with respect to difference in spheroid volume per day (n = 3). Data 
are means ± SEM of three separate experiments each carried out in triplicate. At the 0.05 level, data relative 
to MiaPaCa2 and PANC1 are not significantly different, whereas data relative to MiaPaCa2 are significantly 
different from those relative to BxPC3 (p = 0.003), and data relative to PANC1 are significantly different from 
those relative to BxPC3 (p = 0.002). (B) Microscopic images of PDAC at 72 h (top layer), 120 h (middle layer) 
and 168 h (bottom layer). (C) Live and dead cells were stained after 72H of culturing by Calcein (green) and PI 
(red) respectively. (D) Cytoskeleton organisation was studied by actin staining in all the three cell lines found to 
be on the periphery of cells. Scale bars represent 100 µm.
www.nature.com/scientificreports/
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voltage amplitude, and medium composition14, 30. A video of PANC1 cell assembly is provided as Supplementary 
Information (Supplementary Video S1). Figure 3D and E show typical examples of PANC1 cells on assembly 
ridges (immediately after assembly and after 146 h of culture under continuous perfusion, respectively).
Viable BxPC3, MiaPaCa2 and PANC1 cells were assembled inside the HepaChip® using DEP. When they 
were cultured inside the chip, all three cell types initially adhered to the chip surface. Both BxPC3 (Fig. 4A) 
and PANC1 (Fig. 4B) cells spread on the microstructure and remained viable for several days. Cells grew inside 
the HepaChip® under perfusion with culture medium, as shown by the increase in cell number and density. 
We observed mitosis of both BxPC3 and PANC1 cells, as a clear index of their functionality. Figure 4C shows a 
representative example thereof obtained with BxPC3 cells. On the contrary, MiaPaCa2 cells showed very weak 
adhesion to the collagen-coated surfaces. This fact could be related to the expression, on the plasma membrane 
of these cells, of integrin adhesion receptors with lower affinity for collagen (Manoli S., personal communica-
tion). While some of them spread on the surface during the first 24 hours, others remained in a spherical shape 
Figure 3. HepaChip: (A) Full view of the chip with 8 culture chambers, fluidic inlet and outlet and gold 
electrodes. (B) close up of one chamber containing 2 electrodes and 3 assembly ridges coated with collagen. 
(C) Simulation of flow velocity and trajectories of cells during DEP assembly inside a culture chamber. (D) 
PANC1 cells assembled on one assembly ridge right after assembly. (E) Live/Dead staining of PANC1 cells after 
146 hours of perfused culture inside the HepaChip® chamber.
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and aggregated at columns and edges inside the chip. During the following three days of perfused culture the 
majority of MiaPaCa2 cells was transported out of the chip while vitality of the remaining cells decreased (see 
Supplementary Information Fig. S1).
Hence we focused our attention to BxPC3 and PANC1 cultures only (Fig. 4A and B). When comparing BxPC3 
and PANC1 cultured within the microfluidic chip, we observed the following behaviours:
(1) BxPC3: during DEP BxPC3 cells adhered and spread on the collagen coated ridges until they formed a 
dense layer. During perfused culture of several days they slowly extended up the ramp and formed a thick rim. 
This rim grew thicker with culture time rather than further extending into the channel region (Fig. 4A). After 24 
and 48 h, we observed mainly adherent, flattened cells, which continuously changed their shape. Furthermore, we 
observed small spheroids growing on top of the adherent cells.
Figure 4. In vitro cell growth characteristics of PDAC cells in the HepaChip®. (A) Live/Dead cell staining of 
BxPC3: BxPC3 grow selectively on the ridge. (B) Live/Dead cell staining of PANC1: In contrast the PANC1 
spread as well channel walls and bottom, so the picture on day 6 was taken in two focal planes: on the channel 
and on the ridge. (C) Mitosis of BxPC3: Mitosis was observed inside the chip on the collagen coated area after 
16 h culture. From left to right pictures taken after 0 min – 1 min – 4 min – 16 min using an inverted microscope. 
(D) Cytoskeleton assembly of BxPC3 and (E) of PANC1: Fluorescence images after actin and nucleus staining 
with Phalloidin and DAPI. Scale bars in A and B represent 100 µm, in C represents 10 µm.
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(2) PANC1: during DEP PANC1 cells showed less adhesion to collagen coated areas but tended to slide over 
the surface before adhering. They were incubated for 10 to 15 min in DEP medium and left to sink onto the 
micro structured surface before the DEP medium was exchanged for culture medium. After that, PANC1 adhered 
everywhere in the chip, on collagen coating as well as on pluronic coated ramps of the ridges (Fig. 4B-0), on chan-
nel walls and on gold electrodes. They spread on any of these surfaces and grew one on top of others (Fig. 4B-1 
to B-6). In order to demonstrate the cell growth inside the 3D microstructure, Fig. 4B-6 was taken in two focal 
planes: that of the channel (left) as well as that of the collagen coated ridge (right). It shows that PANC1 also 
formed small aggregates on any of these surfaces after 6 days of cell culture. Overall, PANC1 cells behave inside 
the chip as a spheroid forming type. Actin stained with Phalloidin extended over the entire cytoplasm of both 
BxPC3 and PANC1 cells cultivated in the chip. As expected, it appeared denser along the cell membrane (Fig. 4D 
and E). PANC1 showed additional short actin filaments that extend from the membrane both into the cell and 
outside, a sign of the maintenance of their pro-migratory, cancerous features, even when cultured on the chip. 
The morphological and functional features of the three cell lines cultured as 2D, 3D and inside the chip are sum-
marised in Table 1.
Finally, we tested whether the microfluidic chip could be a useful device for testing drugs in PDAC cells. 
In particular, we tested the effects of Cisplatin, a widely used drug for many cancer types including PDAC, 
on PANC1 cells. Cisplatin exerted cytotoxic activity on PANC1, with IC50 values of 3.25 ± 0.2 μM (n = 2) and 
14.6 ± 1.6 μM (n = 2) in 2D and 3D cultures, respectively. In 3D cultures 100 μM Cisplatin caused a decrease 
in cell viability (roughly 80%) after 72 h of incubation, and caused the spheroids to disaggregate after 72 h of 
treatment (Fig. 5B). We also tested the effects of Cisplatin in vivo, in immunocompromised mice subcutaneously 
injected with PANC1 cells, at 10 mg/kg31. As expected, this Cisplatin dose fully blocked tumour growth after 10 
Culture 
type Cell type Adhesion Spreading Morphology
3D aggregate 
formation + aggregate size Cytoskeleton
2D
BxPC3 Strong
Forms tight cell-
cell clusters or 
islands of clusters 
with spread 
morphology
Epithelial
Forms large uniform 
clusters or islands of 
clusters.
Actin: Long 
and distributed 
across the 
cytoplasm
PANC1 Moderate to strong
Spread 
morphology with 
few round shaped 
cells on top of 
spread cells
Epithelial Forms moderate cell-cell aggregates
Actin: Long 
and distributed 
across the 
cytoplasm
MiaPaCa2 Loose
Both round and 
spread shaped 
cells with few 
elongated feet like 
structures
Epithelial Mostly separate cells with few cell-cell aggregates
Actin: Long and 
localised near the 
membrane level
3D
BxPC3 No adhesion to agarose
Smoothly tight small 
spheroid with no 
visible distinction 
between central and 
peripheral regions
Actin: Short 
and distributed 
around the 
periphery of 
the cell
PANC1 No adhesion to agarose
Loosely assembled 
spheroid with clear 
distinction between 
tightly formed round 
central dormant 
and loosely ruffled 
(and proliferating) 
peripheral regions
Actin: Short 
and distributed 
around the 
periphery of 
the cell
MiaPaCa2 No adhesion to agarose
Moderately tight 
spheroids with visible 
central dormant 
and peripheral 
proliferating regions
Actin: Short 
and distributed 
around the 
periphery of 
the cell
HepaChip
BxPC3 Selective on collagen
On collagen and 
cells
Mostly flat cells 
20–30 µm diameter, 
few round 10 µm cells 
on top
At the edges of the coated 
microstructure w = 20–
80 µm *
Actin: Long 
and distributed 
across the 
cytoplasm
MiaPaca Poor adhesion on collagen
Few cells spread 
on collagen, most 
stay spherical
Mostly spherical, 
5–50 µm, after 24 h 
few flat cells with 
“feet”
Small aggregates at the 
edges of ridges and at pillars 
w = 80–90 µm*
PANC1
On 
microtopography 
independend of 
coating
On any surface 
and on top of 
other cells
Many flat cell with 
“feet”, various shapes, 
spherical ones on top, 
10–50 µm
On the ramps w = 50–
120 µm*
Actin: Long 
and distributed 
across the 
cytoplasm
Table 1. Morphological and functional features of PDAC cells cultured in 2D, 3D and inside the microfluidics 
HepaChip device. *Maximum aggregate thickness in the HepaChip® culture chamber was in the range of the 
measured width of the aggregates on the ramps. It is limited by the 3D geometry of the chamber between 40 µm 
on the assembly ridges and 190 µm inside the channels (see Fig. 3C) if assuming that at maximum aggregates 
can fill the height between the lid of the chamber and this ramp at the channel bottom.
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days (Fig. 5C). The effects of Cisplatin on PANC1 cells cultured inside the microfluidic chamber were also ana-
lysed (Fig. 5D). After 72 h of perfusion with 25 µM Cisplatin in culture medium, a certain reduction of viability 
from 95 to 83% in both chips and a slight decrease of cell density were observed. The highest concentration of 
100 µM Cisplatin perfused through the cell culture chip started to reduce viability from 92 to 85% after 24 h incu-
bation, reaching 68% after 3 days. At this time an overall reduction of the cell density in the chip was observed as 
shown in the yellow framed area of Fig. 5D on the right compared to the inset below that shows the same area of 
this chip before incubation with Cisplatin. Viabilities in the control chips without Cisplatin remained between 90 
and 78% over a culture time of 5 days in total. Overall a trend in concentration dependence of Cisplatin effects is 
evident in the graph in Fig. 5E.
The higher Cisplatin concentration needed to obtain reduction in cell vitality in the chip compared to con-
ventional 2D in vitro cultures could be due either to differences in cellular functions (e.g. presence of a structured 
tridimensional ECM in the chip) or to an unfavourable adsorption of the drug onto the microfluidic device which 
might then result in a lower effective concentration acting on the cells. To test this latter hypothesis, and taking 
into account the fact that Cisplatin is relatively hydrophobic, we tested the recovery of a number of compounds 
covering a wide range with respect to hydrophobicity. Uncoated chips showed a considerable degree of adsorp-
tion, so that that the most hydrophobic compounds tested (Bupropion, Amodiaquine) were recovered at below 
50% even after 3 hours of perfusion. On the contrary, coated chips identical to those used in this study, exhibited 
almost complete recovery after only 1 hour of perfusion (Supplementary Information Fig. S2). Therefore, consid-
ering that Cisplatin was applied over a period of 72 h, adsorption to polymer surfaces can be ruled out as the cause 
for the high doses of the drug needed to affect viability of PANC1 cells.
Figure 5. Effect of cisplatin on PANC1 cells. (A) Dose response curve of Cisplatin on PANC1 cells in 2D 
culture conditions. The calculated IC50 was 3.25 ± 0.2 μM. Data are means ± SD of two separate experiments, 
each carried out in triplicate. (B) Dose response curve of Cisplatin on PANC1 cells in 3D culture conditions. 
The calculated IC50 was 14.6 ± 1.6 μM. Data are means ± SD of two separate experiments, each carried out 
in triplicate. Panels on the right show the live/dead cell staining of the spheroids in control (panel on the 
top), 25 μM (panel in the middle), and 100 μM (panel at the bottom). (C) Effect of cisplatin on PANC1 
cells subcutaneously injected into mice (in vivo). The trend line shows the volume of the masses during the 
duration of experiment, histogram on the right shows the tumour masses of explant from the animals. (D) 
Effect of cisplatin on PANC1 cells inside the HepaChip® under continuous perfusion of 3 µL/min. Live/Dead 
cell staining after 72 h incubation with 0 µM, 25 µM and 100 µM cisplatin; inset: black framed area of the 
chip cell culture before incubation with 100 µM Cisplatin. Scale bars 100 µm. (E) Effect of different cisplatin 
concentrations on PANC1 cells cultured inside the HepaChip®.
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Discussion
In the present paper we examined the possibility of using a microfluidic platform suitable for studying biomo-
lecular characteristics of PDAC cells. Such platform could be further employed to improve diagnosis and prog-
nosis of PDAC as well as for personalised pharmacological testing, in the future. We chose to study PDAC cells 
since PDAC is one of the human cancers with worst prognosis, with a 5-year survival rate less than 6%. PDAC 
malignancy can be traced back to the limited capabilities to diagnose (and treat) the disease in its earliest stages, 
its propensity to migrate and invade surrounding tissues and hence give rise to local and distant metastases, as 
well as to its substantial chemo- and radio-resistance. Overall new strategies are urgently needed to impact PDAC 
treatment and to extend and save PDAC patients’ lives. For these purposes, various cancer model systems26 have 
been developed, from in vitro 2D and 3D cell cultures to whole animal models.
We here provide evidence that PDAC cells can be cultured onto a novel microfluidic chamber, the HepaChip®, 
maintaining cell vitality, morphological appearance and growth characteristics that more closely resemble 3D 
cultures. Furthermore the actin organisation, taken as a functional marker of a proper pro-migratory, neoplastic 
phenotype, showed a typical cancer-type assembly. Several cultures of PDAC cells in microfluidic channels have 
been published that culture one or more cell types entrapped in a hydrogel scaffold containing ECM proteins26, 32. 
Although the microfluidic structures used so far, allow microscopic image acquisition similar to 2D in vitro 
assays32, 33, they do not mimic the flow of nutrients as occurs inside blood vessels and around them. Such a 
flow produces shear forces and pressure, which closely resemble in vivo tissues34, 35. The microfluidic system 
(HepaChip®) we have developed allows for continuous perfusion of the cell culture. Furthermore, viable cells 
are actively assembled in a dense layer inside the HepaChip® culture chamber without entrapping them inside a 
hydrogel that might slow down the transport of nutrients to and metabolites from the cells. The 3D structure of 
the HepaChip® enables the formation of cell aggregates especially in areas of reduced flow between the pillars. 
These aggregates are still in direct contact to the medium flow and hence delivered a continuously high concen-
tration of nutrients. Media perfused through the chip was assumed to be saturated by oxygen upon entering the 
chip as the tubing employed was permeable to oxygen. At a perfusion rate of 3.125 µl/min oxygen was supplied at 
a rate of 1.2 nmol/min to the chip, by far in line with common oxygen perfusion and pressure inside pancreatic 
cancers in vivo36. This means they can also be exposed to a continuously high dose of drug during toxicity tests.
Indeed, we also tested the suitability of the platform for testing chemotherapeutic drugs. We chose to test 
Cisplatin as a model drug, since Platinum-based drugs are used in both the neo-adjuvant and the adjuvant set-
tings for PDAC treatment. One major hindrance when testing chemotherapeutic drugs in vivo (both in preclin-
ical models and in patients) is the frequent lack of response applying drug concentrations derived from in vitro 
data, obtained in standard 2D cultures37–39. We confirmed these findings showing that the IC50s of Cisplatin in 
PANC1 cells cultured in vitro are around 3 μM in 2D cultures, and only slightly higher, 15 μM, in spheroid 3D 
cultures. On the contrary, the dose used to obtain complete growth inhibition (10 mg/kg) in vivo is much higher, 
corresponding to an estimated plasma concentration of 240 μM40. When tested on cells cultured onto the chip, 
Cisplatin decreased PANC1 cell vitality (about 30%) after 72 hours of incubation with high doses (100 μM). This 
dose is much higher than the IC50s determined in in vitro 2D and 3D cultures. Although these are still singular 
experiments and a dose-response assay was not performed, the necessity of higher doses of a chemotherapeutic 
drug to decrease cell viability when applied to a chip are consistent with those previously reported32, 33. Moreover, 
although we cannot compare the results obtained in the chip with those found in mice, our data suggest that the 
effects of Cisplatin perfused in the chip are more similar to those exerted in vivo, e.g. in mice (Fig. 5C). This is 
consistent with data reported in41 showing that the IC50 values of five model drugs, tested in a microfluidic chip 
for in vitro hepatocyte drug toxicity tests, correlate with the IC50s determined in vivo. Overall our data suggest 
that PDAC cells, when cultured in the microfluidic chip under continuous perfusion, withstand incubation with 
Cisplatin at higher doses compared to classical in vitro cultures. Our data showing no adsorption of the drug to 
polymer surfaces, lead to exclude drug adsorption as the cause for this chemo- resistance. The proper culture 
in the chip needs cell adhesion to collagen, that can re-establish the cell-cell and cell-ECM interactions that 
mimic the real tissues42. Hence we hypothesise that when PDAC cells are cultured in the chip behave differ-
ently compared to 2D. For example they could form a thin layer of ECM around them under flow conditions 
which could shield from perfused compounds. Consistently, the ECM is known to sustain tumour chemore-
sistance43, through the triggering of different molecular mechanism, including an up regulation of the Multi 
Drug Resistance p-glycoprotein44. Although we will deepen these points in the future, from the present paper it 
appears that tumour cell cultures onto the HepaChip® provide a more realistic and predictive response towards 
chemotherapeutic agents when compared to 2D cultures of the same cell type.
Overall, we provide a novel microfluidic platform that could be fruitfully transferred to both clinical and 
pharmaceutical testing, in order to provide biological characteristics as well as responses to drug treatments, to 
improve a personalised approach to PDAC.
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